Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Celltrion Sees Double-Digit Growth In Sales And Profit

As Company’s Biosimilars Strategy Continues To Deliver

Executive Summary

South Korea’s Celltrion saw a double-digit jump in sales and operating profit in 2020 based on continued growth for its leading biosimilars. Meanwhile, the company is pursuing its strategy of developing at least one biosimilar annually.

You may also be interested in...



Ups And Downs See Mid-Table Players Shift Position

Mid-table players jostle for position as we continue to work our way through Generics Bulletin’s annual Top 50, with mixed fortunes over the past year seeing some companies rise up the rankings as others decline.

Celltrion’s Kim Emphasizes Innovation As Pipeline Grows

Celltrion will adopt a “next generation” innovative approach to developing biosimilars as it continues to bolster its pipeline, HoUng Kim, head of Celltrion Healthcare’s medical and marketing division, tells Generics Bulletin in an exclusive interview. But the firm sees the US interchangeability designation as an “unnecessary” regulatory barrier.

Celltrion Offers Real-World Data On Rituximab

South Korea’s Celltrion has announced positive results from its recent study on the real-world clinical effectiveness and safety of its Truxima (rituximab) or CT-P10 biosimilar in patients with diffuse large B-cell lymphoma. The company presented its findings at the recently held European Hematology Association 2021 virtual congress. 

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB150739

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel